Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I combination immunotherapy with HSP70/GPC3 peptides, IMP321 and Hiltonol in advanced or metastatic solid cancer
jRCTs061180058Phase 1Completed
- Sponsor
- Not applicable
- Start
- Jan 2016
- Modality
- Vaccines & Immunotherapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of hsp70-derived peptide vaccine, GPC3-derived peptide, eftilagimod alpha and poly iclc in pancreatic cancer (PC), colorectal cancer (CRC), gastric cancer (GC) and 4 more, sponsored by Not applicable. Primary endpoint: Safety. Started Jan 2016; status: completed.
02
Drugs
hsp70-derived peptide vaccineGPC3-derived peptideeftilagimod alphapoly iclc
03
Conditions
pancreatic cancer (PC)colorectal cancer (CRC)gastric cancer (GC)esophageal cancerhepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCTs061180058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs061180058.